Lipophilic statins do not affect the antiplatelet potency of clopidogrel

dc.contributor.authorTselepis, A. D.en
dc.contributor.authorGoudevenos, J. A.en
dc.date.accessioned2015-11-24T16:41:07Z
dc.date.available2015-11-24T16:41:07Z
dc.identifier.issn0953-7104-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/8368
dc.rightsDefault Licence-
dc.subjectacute coronary syndromesen
dc.subjectclopidogrelen
dc.subjectplateletsen
dc.subjectstatinsen
dc.subjectacute coronary syndromesen
dc.subjectflow-cytometryen
dc.subjectatorvastatinen
dc.titleLipophilic statins do not affect the antiplatelet potency of clopidogrelen
heal.abstractThis letter to the editor discusses the results of the recently published study by Smith et al. which demonstrated that lipophilic statins metabolized through the cytochrome P-450 isoform 3A4 (CYP3A4) do not influence the antiplatelet effectiveness of clopidogrel in patients undergoing elective percutaneous coronary intervention. These results as well as those of other recent studies suggest that there is no adverse interaction between clopidogrel and CYP3A4-metabolized statins, during the maintenance phase of therapy (i.e., 2 or more days after the drug co-administration) either at the platelet or at the clinical level.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDoi 10.1080/09537100500124525-
heal.identifier.secondary<Go to ISI>://000230428600014-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1080/09537100500124525-
heal.journalNamePlateletsen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: